Organon & Co. (OGN)
Organon & Co. - Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE®(tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Organon & Co. - Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE®(tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General